Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Chiauranib in Relapsed/Refractory Small Cell Lung Cancer: a Single-arm, Open-label, Multi-center, Exploratory Phase Ib Study

NCT03216343 is registered in ClinicalTrials.gov with Chipscreen Biosciences, Ltd. as lead sponsor.

NCT NCT03216343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03216343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Chiauranib in Relapsed/Refractory Small Cell Lung Cancer: a Single-arm, Open-label, Multi-center, Exploratory Phase Ib Study
Lead sponsor
Chipscreen Biosciences, Ltd.
Phase
Phase 1
Overall status
Completed
Start date
November 9, 2017
Completion date
May 15, 2023
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer